Velozell

About

Velozell helps biotech, CDMOs, and tool vendors turn early-stage bioprocess ideas into GMP-ready, adoptable solutions. We’re bioreactor-fluent—wave, STR (HT to 2,000 L), and adherent fixed-bed—with deep MSAT/CMC experience across cell & gene therapy, vectors, and RNA. We design QbD/DoE studies, execute tech transfer, align documentation for IND/IMPD/BLA/MAA, and package capabilities into clear, scalable offerings. What we deliver: reliable scale-up/transfer, lower deviation rates, faster time-to-run, and product decisions grounded in operator reality. Focus areas: Bioreactor strategy & scale-up • Tech transfer & lifecycle validation • QbD/DoE & comparability • MSAT/CMC readiness • Digital foundations (CRM/CMMS/ERP) • CGT vector & cell expansion

Details

• Founded: 2019
• Company Size: 1 employees
• Headquarters: Amsterdam, North Holland
• Specialties: Cell and Gene Therapy, Bioreactor strategy, single-use bioreactor, Tech transfer, MSAT, CMC, Quality by Design, Process Characterization, Bioreactor design, Organization scale-up, Process simplification